- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02102880
The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects
April 6, 2022 updated by: Gerhard Garhofer, Medical University of Vienna
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component.
Given that it is known that impaired regulation of choroidal vascular tone is present in patients with AMD, the current study seeks to investigate whether genetic polymorphisms in risk alleles for AMD are associated with altered choroidal blood flow regulation in healthy subjects.
For this purpose a total of 220 healthy volunteers will be included.
Choroidal blood flow regulation will be evaluated by measuring choroidal blood flow during isometric exercise.
In addition, flicker induced vasodilatation will be studied and retinal vessel calibers will assessed, as well as retinal thickness and macular pigment optical density.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
220
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gerhard Garhofer, MD
- Phone Number: 2981 0034140400
- Email: gerhard.garhoefer@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Department of Clinical Pharmacology, Medical University of Vienna
-
Contact:
- Gerhard Garhöfer, MD
- Phone Number: 2981 0043140400
- Email: gerhard.garhoefer@meduniwien.ac.at
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women aged between 18 and 45 years, nonsmokers
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Systolic blood pressure < 160 mmHg, diastolic blood pressure < 90 mmHg
- Normal ophthalmic findings, ametropia less than 3 diopters
Exclusion Criteria:
- Regular use of medication
- Abuse of alcoholic beverages
- Participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug (except hormonal contraceptives)
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- History or family history of epilepsy
- Pregnancy, planned pregnancy or lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Healthy Subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Choroidal blood flow during isometric exercise (LDF)
Time Frame: 1 day
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Flicker induced vasodilatation, expressed as percent change to baseline (DVA)
Time Frame: 1 day
|
1 day
|
Genotyping (PCR)
Time Frame: 1 day
|
1 day
|
Retinal vessel calibers and AV- ratio (DVA)
Time Frame: 1 day
|
1 day
|
Laser Speckle Flowmetry (LSFG)
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Calzetti G, Fondi K, Bata AM, Luft N, Wozniak PA, Witkowska KJ, Bolz M, Popa-Cherecheanu A, Werkmeister RM, Schmidl D, Garhofer G, Schmetterer L. Assessment of choroidal blood flow using laser speckle flowgraphy. Br J Ophthalmol. 2018 Dec;102(12):1679-1683. doi: 10.1136/bjophthalmol-2017-311750. Epub 2018 Feb 22.
- Witkowska KJ, Bata AM, Calzetti G, Luft N, Fondi K, Wozniak PA, Schmidl D, Bolz M, Popa-Cherecheanu A, Werkmeister RM, Garhofer G, Schmetterer L. Optic nerve head and retinal blood flow regulation during isometric exercise as assessed with laser speckle flowgraphy. PLoS One. 2017 Sep 12;12(9):e0184772. doi: 10.1371/journal.pone.0184772. eCollection 2017.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2015
Primary Completion (Anticipated)
September 2, 2023
Study Completion (Anticipated)
September 2, 2023
Study Registration Dates
First Submitted
March 21, 2014
First Submitted That Met QC Criteria
March 31, 2014
First Posted (Estimate)
April 3, 2014
Study Record Updates
Last Update Posted (Actual)
April 7, 2022
Last Update Submitted That Met QC Criteria
April 6, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPHT-040214
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
-
Apellis Pharmaceuticals, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States, Australia
Clinical Trials on the polymerase chain reaction (PCR)
-
Assiut UniversityNot yet recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEndocarditis InfectiveItaly
-
University Hospital, ToursNot yet recruitingCertain Disorders Involving the Immune MechanismFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingKidney Transplant; Complications | Diarrhoea;Acute | Diarrhea Infectious
-
Assistance Publique Hopitaux De MarseilleTerminatedSystemic Lupus Erythematosus (SLE)France
-
John H. Stroger HospitalUniversity of Illinois at ChicagoUnknownPituitary TumorUnited States
-
Hunter College of City University of New YorkUniversidad Autonoma Juan Misael Saracho; Gobierno Autonomo Departamental De... and other collaboratorsCompleted
-
Hospices Civils de LyonUnknown
-
Northwestern UniversityCompletedPneumonia | Methicillin-Resistant Staphylococcus AureusUnited States
-
Assistance Publique - Hôpitaux de ParisGE Healthcare; Institut National de la Santé Et de la Recherche Médicale, France and other collaboratorsCompleted